Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Clinical trial NCT03135951 · COMPLETED
Trial details
- NCT number
- NCT03135951
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-11
- Primary completion
- 2018-02-19
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.